Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs
Immunology
[키워드] 2019 coronavirus disease
ACE2
activating
acute respiratory distress
acute respiratory syndrome
addition
Admissions
alveolar
ARDS
binding
caused
coronavirus
Coronavirus infections
COVID19
cytokine
develop
drug
enzyme
Evidence
expressed
Factor
Fighting
flu
glycoprotein
IFNγ
IL-4
IL10
IL1B
Ill
Immune cell
immune response
immunosuppressive drug
increase in
infected patients
Inflammation
intensive care
interstitial
interstitial pneumonia
involved
IP10
macrophages
majority
MCP1
multiorgan failure
offlabel drug use
other molecule
Patient
peptides
Pneumocytes
pro-inflammatory cytokines
PRR
reaction
reported
Symptom
syndrome
therapeutic option
therapeutic target
tissue
Vasoactive
virus
[DOI] 10.3389/fimmu.2020.01201 PMC 바로가기 [Article Type] Immunology
[DOI] 10.3389/fimmu.2020.01201 PMC 바로가기 [Article Type] Immunology